Shares of Rezolute surged 11.3% to $4.45 after Guggenheim analyst Debjit Chattopadhyay raised his price target to $11.00 and designated the stock a "Best Idea" — a high-conviction call that forces investors to weigh promising clinical data against a company that still generates zero revenue.
Six of Eight Trial Patients Hit the Key Goal, and That Changed the Math
The catalyst is Rezolute's Phase 3 trial of its antibody treatment for tumor-related hyperinsulinism — a rare condition causing dangerous drops in blood sugar. With eight of a planned 16 patients enrolled, six have already met the primary endpoint: at least a 50% reduction in the intravenous glucose they need to stay alive.
All patients who completed the main phase chose to continue treatment, with no drug-related side effects reported over up to six months.
Full results are expected in the second half of 2026. That readout is the single most important date on Rezolute's calendar.
A Wave of Upgrades Signals a Sentiment Shift After Last Year's Setback
In December 2025, a separate trial in a different form of hyperinsulinism failed its primary endpoint — the drug worked, but a strong placebo effect wiped out statistical significance. That crushed the stock below $1.50. Now at least five firms have raised targets or upgraded the stock in June alone, including Maxim (to $14), Wedbush (to $6), BTIG (to $6), and Citizens JMP (upgrade to Outperform). Guggenheim's $11 target is the Street's most aggressive among major brokerages, implying a 147% gain from today's price.
No Revenue Today, But Analysts See Billions — Eventually
Wall Street consensus forecasts Rezolute's 2026 revenue at exactly $0. The entire thesis hinges on future drug approval. Analyst models project revenue could reach roughly $66 million by 2027 and balloon to over $5 billion by 2028 — wildly ambitious figures contingent on regulatory success and commercial execution. The company held $11.9 million in cash and $121 million in marketable securities as of year-end 2025 , giving it runway but no margin for trial delays.
The Bottom Line for Shareholders: Binary Risk at a Discount At $4.45, RZLT trades at roughly 40% of Guggenheim's target, meaning the market is pricing in substantial doubt. The stock's 52-week range of $1.07–$11.46 tells the story: this is a company whose value swings violently with each clinical headline. The upcoming full trial readout will either validate the rally or deflate it. Until then, the Guggenheim call is a bet on binary data — not on a business that exists yet.